Monashee Investment Management LLC Buys New Stake in Kura Oncology, Inc. (NASDAQ:KURA)

Monashee Investment Management LLC purchased a new position in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 120,000 shares of the company’s stock, valued at approximately $1,270,000. Monashee Investment Management LLC owned approximately 0.18% of Kura Oncology as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Nisa Investment Advisors LLC boosted its holdings in Kura Oncology by 147.3% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,325 shares of the company’s stock valued at $28,000 after acquiring an additional 1,385 shares during the period. Point72 Middle East FZE acquired a new stake in Kura Oncology during the 4th quarter worth approximately $115,000. Exchange Traded Concepts LLC purchased a new position in Kura Oncology in the 2nd quarter valued at approximately $118,000. Virtu Financial LLC acquired a new position in shares of Kura Oncology in the second quarter worth $129,000. Finally, Jump Financial LLC purchased a new stake in shares of Kura Oncology during the first quarter worth $146,000.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded up $0.08 during trading on Monday, reaching $9.64. The company’s stock had a trading volume of 54,833 shares, compared to its average volume of 736,208. The company has a 50-day moving average price of $8.79 and a two-hundred day moving average price of $10.37. Kura Oncology, Inc. has a fifty-two week low of $7.41 and a fifty-two week high of $16.14. The firm has a market cap of $715.98 million, a PE ratio of -4.73 and a beta of 0.65. The company has a current ratio of 16.71, a quick ratio of 16.71 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. StockNews.com began coverage on Kura Oncology in a research note on Thursday, October 5th. They set a “sell” rating for the company. Wedbush decreased their price objective on shares of Kura Oncology from $40.00 to $37.00 and set an “outperform” rating for the company in a research report on Friday, November 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of Kura Oncology in a research note on Thursday, September 7th. Scotiabank began coverage on Kura Oncology in a report on Thursday, July 27th. They set a “sector perform” rating and a $10.50 price target for the company. Finally, Bank of America initiated coverage on Kura Oncology in a report on Friday, August 11th. They issued a “buy” rating and a $31.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $27.31.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.